Results 161 to 170 of about 5,926 (192)
Some of the next articles are maybe not open access.
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire +1 more source
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire +1 more source
Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
American Journal of Clinical OncologyBreast and prostate cancer are among the most commonly diagnosed cancers worldwide. Recent advances in tumor sequencing and gene studies have led to a paradigm shift from treatment centered on the type of tumor to therapy more focused on specific immune phenotype markers and molecular alterations.
Zaheer Qureshi +4 more
openaire +2 more sources
Talazoparib: a new biomarker-directed therapy in advanced prostate cancer
The Lancet Oncology, 2021Vincenza, Conteduca, Ugo, De Giorgi
openaire +2 more sources
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Medicom Conference Report WCLC 2022, 2022Jonathan Goldman, Robert van den Heuvel
openaire +1 more source